Company Growth (employees)
Vertex Pharmaceuticals was founded in 1989 and is headquartered in Boston, US
Key People at Vertex Pharmaceuticals
Larry Bock
Co-Founder
Ian F. Smith
Executive Vice President & CFO
Stuart A. Arbuckle
Executive Vice President and Chief Commercial Officer
Amit K. Sachdev
Senior Vice President,Global Government Strategy, Market Access and Value
Vertex Pharmaceuticals Office Locations
Vertex Pharmaceuticals has an office in Boston
Boston, US (HQ)
50 Northern Ave
Vertex Pharmaceuticals Metrics
Vertex Pharmaceuticals Financial Metrics
Vertex Pharmaceuticals's revenue was reported to be $1.7 b in FY, 2016 which is a 65% increase from the previous period.
Revenue (FY, 2016) | $1.7 b |
Revenue growth (FY, 2015 - FY, 2016), % | 65% |
Net income (FY, 2016) | ($84 m) |
EBIT (FY, 2016) | $9.9 m |
Market capitalization (19-May-2017) | $29.4 b |
Closing share price (19-May-2017) | $117.9 |
Cash (31-Dec-2016) | $1.2 b |
Vertex Pharmaceuticals's current market capitalization is $29.4 b.
| FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | |
|---|---|---|---|---|
Revenue | $1.2 b | $580.4 m | $1 b | $1.7 b |
Revenue growth, % | (52%) | 78% | 65% | |
Operating expense total | $2.1 b | $1.3 b | $1.5 b | $1.7 b |
EBIT | ($903.4 m) | ($692.4 m) | ($466.9 m) | $9.9 m |
EBIT margin, % | (75%) | (119%) | (45%) | 1% |
Interest expense | $22.7 m | $72.9 m | $84.2 m | $81.4 m |
Interest income | $22.7 m | |||
Pre tax profit | ($976.1 m) | |||
Income tax expense | ($288.6 m) | $7 m | $30.4 m | $16.7 m |
Net Income | ($687.6 m) | ($742.7 m) | ($588.2 m) | ($84 m) |
| FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | |
|---|---|---|---|---|
Cash | $569.3 m | $625.3 m | $714.8 m | $1.2 b |
Accounts Receivable | $85.5 m | $76 m | $177.6 m | $201.1 m |
Inventories | $14.1 m | $30.8 m | $57.2 m | $77.6 m |
Current Assets | $1.6 b | $1.5 b | $1.4 b | $1.8 b |
PP&E | $696.9 m | $715.8 m | $697.7 m | $698.4 m |
Goodwill | $31 m | $39.9 m | $50.4 m | $50.4 m |
Total Assets | $2.3 b | $2.3 b | $2.5 b | $2.9 b |
Accounts Payable | $49.3 m | $71.2 m | $74.9 m | $61.5 m |
Current Liabilities | $397.8 m | $368.3 m | $506.3 m | $792.5 m |
Additional Paid-in Capital | $5.3 b | $5.8 b | $6.2 b | $6.5 b |
Retained Earnings | ($4 b) | ($4.7 b) | ($5.3 b) | ($5.4 b) |
Total Equity | $1.1 b | $1.3 b | ||
Financial Leverage | 2.3 x | 2.2 x |
| FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | |
|---|---|---|---|---|
Net Income | ($687.6 m) | ($742.7 m) | ($588.2 m) | ($84 m) |
Depreciation and Amortization | $48.4 m | $63.3 m | $62.3 m | $61.4 m |
Accounts Receivable | $53.4 m | $7.4 m | ($100 m) | ($33 m) |
Inventories | $7.1 m | ($16 m) | ($23 m) | ($16 m) |
Accounts Payable | ($49.2 m) | $25 m | ($1.7 m) | ($11.7 m) |
Cash From Operating Activities | ($51.6 m) | ($513.2 m) | ($365.4 m) | |
Cash From Investing Activities | ($54.1 m) | $74 m | $268.9 m | $104.5 m |
Cash From Financing Activities | $180.9 m | $497.4 m | $188.9 m | $133.3 m |
Interest Paid | $11 m | $8.7 m | $85.6 m | $83.7 m |
Income Taxes Paid | $2.8 m | $1.2 m | $1.8 m |
| Y, 2016 | |
|---|---|
Revenue/Employee | $830.3 k |
Financial Leverage | 2.2 x |
